{"brief_title": "Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia", "brief_summary": "The purpose of this study is to evaluate whether weight-based or fixed starting doses result in comparable hemoglobin increases and treatment effects in patients with heart failure and anemia.", "condition": ["Congestive Heart Failure", "Anemia"], "intervention_type": ["Drug"], "intervention_name": ["Darbepoetin Alfa"], "criteria": "Inclusion Criteria: - Symptomatic CHF for at least 3 months - Reduced left ventricular ejection fraction - Stable heart failure medication - Hemoglobin concentration between 9.0 and 12.5 g/dL Exclusion Criteria: - Hypertension - Unstable angina pectoris or recent myocardial infarction - Likely to receive cardiac transplant - Major organ transplant (e.g., lung, liver, heart) or in renal replacement therapy (e.g., dialysis) - Recent or current treatment for malignancy - Systemic hematologic disease - Anemia due to acute or chronic bleeding - Recent Epogen\u00ae or darbepoetin alfa therapy - Recent blood transfusion", "gender": "All", "minimum_age": "21 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Anemia", "mesh_term": ["Heart Failure", "Anemia", "Darbepoetin alfa"], "id": "NCT00086086"}